Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

OBJECTIVE: To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. METHODS: This phase II double-blinded study randomised 147 patients (1:1:1) to receive monthly intravenous anifrolumab basic reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayne, David, Rovin, Brad, Mysler, Eduardo F, Furie, Richard A, Houssiau, Frederic A, Trasieva, Teodora, Knagenhjelm, Jacob, Schwetje, Erik, Chia, Yen Lin, Tummala, Raj, Lindholm, Catharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921596/
https://www.ncbi.nlm.nih.gov/pubmed/35144924
http://dx.doi.org/10.1136/annrheumdis-2021-221478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921596/
https://www.ncbi.nlm.nih.gov/pubmed/35144924
http://dx.doi.org/10.1136/annrheumdis-2021-221478

Ejemplares similares